Table 2.
Sequences of Signaling Probes Used
| HIV | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3TTTGCATGGCTGCTTGATGTC-3′ |
| HCV | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3AAGACAGTAGTTCCTCACAGGG |
| Hfe | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3CACCCAGGCCTGGATCAGC-3′ |
| ACE | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3CTAGAGAAATGGGAGAAAGGAT3′ |
| fas | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3GATGCAGGCCTTCCAAGTTCTG3′ |
| bax | [Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3TCTGCAGCTCCATGTTACTGTC |
| p53 (1) | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3GGGGGTGTGGAATCAACCCACA3′ |
| p53 (2) | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3TGTGCTGTGACTGCTTGTAGAT3′ |
| p21 | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3GGCCAAGGCCCCGCACACGCTC3′ |
| bcl-2 | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3GAAGAGCTCCTCCACCACCGTG3′ |
| Actin | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3TGCACATGCCGGAGCCGTTGTC3′ |
| GAPDH | 5′[Fc]C[Fc]G[Fc]C[Fc]GCTTA[Fc]C[Fc]G[Fc]C[Fc]G(EO)3GGGATCTCGCTCCTGGAAGATG3′ |
The modified adenine is referred to as [Fc] in the signaling probes shown here. The portion of the signaling probe complementary to the target is at the 3′ end and is separated from the ferrocene-labeled tail by a spacer comprised of three ethylene glycol units, abbreviated (EO)3.